Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
Revenue (TTM)
$311 Mln
Net Profit (TTM)
$-158 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
24.51
EV/EBITDA
-3.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
10,766,600
CFO
$965.34 Mln
EBITDA
$936.58 Mln
Net Profit
$-607.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lannett (LCI)
| -98.6 | 66.9 | -98.2 | -98.8 | -89.9 | -78.1 | -52.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Lannett (LCI)
| -67.8 | -75.2 | -26.1 | 77.8 | -78.4 | 5.2 | -45.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution... finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania. Read more
CEO & Director
Mr. Timothy C. Crew
VP of Fin., CFO & Principal Accounting Officer
Mr. John Kozlowski
Headquarters
Trevose, PA
Website
The share price of Lannett Co Inc (LCI) is $0.03 (NYSE) as of 20-Jun-2023 09:30 EDT. Lannett Co Inc (LCI) has given a return of -89.89% in the last 3 years.
Since, TTM earnings of Lannett Co Inc (LCI) is negative, P/E ratio is not available.
The P/B ratio of Lannett Co Inc (LCI) is 1.84 times as on 20-Jun-2023, a 67 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Lannett Co Inc (LCI) are Rs -- and Rs -- as of 02-Apr-2026.
Lannett Co Inc (LCI) has a market capitalisation of $ 7 Mln as on 20-Jun-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Lannett Co Inc (LCI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.